Results 131 to 140 of about 35,022 (298)

Rare but relevant: MDMA and hyponatraemia

Addiction, EarlyView.
Abstract Conventionally used for its stimulant, empathogenic and entactogenic effects, 3,4‐methylenedioxymethamphetamine (MDMA, ecstasy) is one of the most commonly used psychoactive drugs, specifically among young adults and in nightlife and recreational party contexts.
Maria Rita Garcia, Nelson G. M. Gomes, Diana Dias‐da‐Silva   +2 more
wiley   +1 more source

Differential Mortality Association of Loop Diuretic Dosage According to Blood Urea Nitrogen and Carbohydrate Antigen 125 Following a Hospitalization for Acute Heart Failure [PDF]

, 2012
Julio Núñez, Eduardo Núñez, Gema Miñana, Vicent Bodı́, Gregg C. Fonarow, Vicente Bertomeu‐González, Patricia Palau, Pilar Merlos, Silvia Mastrolembo Ventura, Francisco J. Chorro, Pau Llàcer, Juan Sanchís   +11 more
openalex   +1 more source

Use of sodium‐glucose cotransporter‐2 inhibitors among older adults with type 2 diabetes mellitus in British Columbia

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Clinical guidelines recommend sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) for individuals with type 2 diabetes mellitus (T2DM) and established or high risk of cardiorenal disease. This study examined real‐world SGLT2i use patterns among older adults with T2DM in British Columbia, Canada.
Hanin Harbi, Gregory Carney, Colin Dormuth, Jacob Volmer Stidsen, Iliana Lega, Lisa M. McCarthy, Guillaume Grenet, Anshula Ambasta, Raha Eskandari, Anton Pottegård, Wade Thompson   +10 more
wiley   +1 more source

The Effect of Loop Diuretics on 28-Day Mortality in Patients With Acute Respiratory Distress Syndrome [PDF]

, 2021
Rui Zhang, Hui Chen, Zhiwei Gao, Meihao Liang, Haibo Qiu, Yi Yang, Ling Liu   +6 more
openalex   +1 more source

Congestion, decongestion, renal function and diuretics in (ESC) heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 730-732, April 2025.
Jan Biegus, Piort Gajewski, Piotr Ponikowski   +2 more
wiley   +1 more source

Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world (STEER)

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To assess the real‐world effectiveness of semaglutide versus tirzepatide in reducing major adverse cardiovascular events (MACE) among patients with overweight/obesity and established atherosclerotic cardiovascular disease (ASCVD) without diabetes in an insured US population.
Lauren Wilson, Zhenxiang Zhao, Victoria Divino, Matthew Bassan, Bríain Ó. Hartaigh, Signe Stensen, Kerem Ozer   +6 more
wiley   +1 more source

Resistance to Loop Diuretics: How to Address it in the Current Scenario? [PDF]

, 2023
Simone Louise Savaris, Fernanda Almeida Andrade, Pedro Vellosa Schwartzmann   +2 more
openalex   +1 more source

Risk of acute pancreatitis with DPP‐4 inhibitors versus SGLT2 inhibitors in medication‐naïve individuals with diabetes: A target trial emulation

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims We investigated whether dipeptidyl peptidase‐4 inhibitor (DPP‐4i) use was associated with a higher risk of acute pancreatitis compared with sodium–glucose cotransporter 2 inhibitor (SGLT2i) use in antidiabetic medication‐naïve individuals.
Takashi Tatewaki, Akira Okada, Yuya Kimura, Hideo Yasunaga   +3 more
wiley   +1 more source

Association of Continuation of Loop Diuretics at Hemodialysis Initiation with Clinical Outcomes [PDF]

, 2018
Scott Sibbel, Adam G. Walker, Carey Colson, Francesca Tentori, Steven M. Brunelli, Jennifer E. Flythe   +5 more
openalex   +1 more source

Effects of sotagliflozin on markers of volume status and sodium handling in patients with type 1 diabetes: A biomarker analysis of the inTandem3 clinical trial

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Sotagliflozin, an inhibitor of sodium‐glucose co‐transporter (SGLT)‐1 and 2, reduces albuminuria, slows GFR decline, and may have diuretic and osmoregulatory effects. The effect of sotagliflozin added to insulin was assessed on markers of neurohormone activation and volume homeostasis in patients with type 1 diabetes (T1D).
Massimo Nardone, Erik Moedt, Hiddo J. L. Heerspink, Michael J. Davies, Manon Girard, David Z. I. Cherney, Marcel H. A. Muskiet   +6 more
wiley   +1 more source